查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1911944

抗血栓藥物市場規模、佔有率和成長分析（按類型、藥物類別、適應症、給藥途徑、最終用戶和地區分類）－2026-2033年產業預測

Antithrombotic Drugs Market Size, Share, and Growth Analysis, By Type (Apixaban, Debigatran), By Drug Class (Thrombolytic Drugs, Anti-Platelet Drugs), By Indication, By Route of Administration, By End User, By Region - Industry Forecast 2026-2033.
出版日期: | 出版商: SkyQuest | 英文 176 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計到 2024 年，全球抗血栓藥物市場規模將達到 522.2 億美元，到 2025 年將達到 563.5 億美元，到 2033 年將達到 1035.3 億美元，預測期（2026-2033 年）的複合年成長率為 7.9%。

抗血栓藥物市場受到心血管疾病盛行率上升、老年人口不斷成長以及對新型口服抗凝血藥物（NOACs）需求日益成長的顯著影響。心血管疾病，包括心房顫動和靜脈血栓栓塞症，是全球主要的死亡原因，這進一步增加了對有效抗血栓治療的需求。老年人群尤其容易患血栓性疾病，從而擴大了患者群體。Dabigatran和利伐沙班等NOACs因其使用方便、藥物交互作用少、出血風險低而迅速普及，推動了市場擴張。然而，出血風險增加、NOACs價格昂貴、消化器官系統併發症、嚴格的監管以及對副作用的擔憂等挑戰仍然限制市場成長。

全球抗血栓藥物市場促進因素

心房顫動、深層靜脈栓塞症和中風等心血管疾病發生率的不斷上升，是推動抗血栓藥物需求成長的主要因素。人口成長、久坐的生活方式以及METABOLIC INC.症候群的流行等因素共同凸顯了抗凝血和抗血小板藥物的重要性。這些治療方法不僅對急性疾病的即時控制至關重要，而且對長期降低心血管風險也至關重要。隨著人們對這些健康問題的認知不斷提高，抗血栓藥物市場預計將會擴大，這反映了對有效治療方案的需求。

限制全球抗血栓藥物市場的因素

由於抗血栓藥物本身存在出血風險，尤其是在老年患者和合併其他疾病的患者中，抗血栓藥物市場面臨嚴峻的挑戰。這種風險的增加使臨床決策更加複雜，可能需要持續監測、調整劑量，甚至停止治療。此類安全隱患會削弱醫療服務提供者的信心，並導致病患依從性降低。因此，這些因素會對抗血栓治療的整體市場滲透率和長期維持治療的療效產生深遠的影響，最終影響患者的治療結果。

全球抗血栓藥物市場趨勢

全球抗血栓市場正經歷著向新一代標靶治療的重大轉變，這些療法有望在凝血因子調節方面實現更高的特異性。這種創新方法專注於開發超標靶治療方法，以降低出血風險並提供持久的治療效果。透過針對特定的疾病進程，這些先進的抗血栓藥物旨在最大限度地減少與傳統療法相關的副作用，並為更個人化的治療策略鋪平道路。因此，醫療專業人員能夠更好地平衡凝血預防和出血控制，從而滿足患者不斷變化的需求，並推動抗血栓市場的成長。

目錄

介紹

  • 調查目標
  • 調查範圍
  • 定義

調查方法

  • 資訊收集
  • 二手資料和一手資料方法
  • 市場規模預測
  • 市場假設與限制

執行摘要

  • 全球市場展望
  • 供需趨勢分析
  • 細分市場機會分析

市場動態與展望

  • 市場規模
  • 市場動態
    • 促進因素和機遇
    • 限制與挑戰
  • 波特分析

關鍵市場考察

  • 關鍵成功因素
  • 競爭程度
  • 關鍵投資機會
  • 市場生態系統
  • 市場吸引力指數（2025）
  • PESTEL 分析
  • 總體經濟指標
  • 價值鏈分析
  • 定價分析
  • 案例研究
  • 顧客購買行為分析

全球抗血栓藥物市場規模（按類型和複合年成長率分類）（2026-2033 年）

  • Apixaban
  • 德比加特蘭
  • 艾多沙班
  • 磺達肝癸鈉
  • 肝素
  • Rivaroxaban

全球抗血栓藥物市場規模（依藥物類別分類）及複合年成長率（2026-2033 年）

  • 溶栓藥物
  • 抗血小板藥物
  • 抗凝血劑
  • 其他

全球抗血栓藥物市場規模（按適應症和複合年成長率分類）（2026-2033 年）

  • 心房顫動
  • 中風
  • 深層靜脈栓塞症（DVT）
  • 肺動脈栓塞（PE）
  • 其他

全球抗血栓藥物市場規模（依給藥途徑及複合年成長率分類）（2026-2033 年）

  • 口服
  • 注射
  • 其他

全球抗血栓藥物市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

  • 醫院
  • 專科診所
  • 居家醫療
  • 其他

全球抗血栓藥物市場規模（依分銷管道分類）及複合年成長率（2026-2033 年）

  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 其他

全球抗血栓藥物市場規模及複合年成長率（2026-2033）

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 義大利
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地區
  • 中東和非洲
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲地區

競爭資訊

  • 前五大公司對比
  • 主要企業的市場定位（2025 年）
  • 主要市場參與者所採取的策略
  • 近期市場趨勢
  • 公司市佔率分析（2025 年）
  • 主要企業公司簡介
    • 公司詳情
    • 產品系列分析
    • 依業務板塊進行公司股票分析
    • 2023-2025年營收年比比較

主要企業簡介

  • F. Hoffmann-La Roche Ltd.（Switzerland）
  • Teva Pharmaceutical Industries Ltd.（Ireland）
  • Sanofi（France）
  • Pfizer Inc.（US）
  • GlaxoSmithKline plc（UK）
  • Novartis AG（Switzerland）
  • Merck & Co., Inc.（US）
  • Allergan（Ireland）
  • AstraZeneca（UK）
  • Johnson & Johnson Private Limited（US）
  • Hikma Pharmaceuticals PLC（UK）
  • Fresenius Kabi AG（Germany）
  • Eisai Co., Ltd.（Japan）
  • Bristol-Myers Squibb Company（US）
  • Bayer AG（Germany）
  • DAIICHI SANKYO COMPANY, LIMITED（Japan）

結論與建議

簡介目錄
Product Code: SQMIG35I2432

Global Antithrombotic Drugs Market size was valued at USD 52.22 Billion in 2024 and is poised to grow from USD 56.35 Billion in 2025 to USD 103.53 Billion by 2033, growing at a CAGR of 7.9% during the forecast period (2026-2033).

The market for antithrombotic drugs is significantly influenced by the increasing prevalence of cardiovascular diseases, a growing geriatric population, and a rising demand for novel oral anticoagulants (NOACs). Cardiovascular conditions, including atrial fibrillation and venous thromboembolism, represent a leading cause of mortality globally, thereby heightening the need for effective antithrombotic therapies. The elderly are particularly susceptible to thrombotic disorders, expanding the patient demographic. The popularity of NOACs, such as dabigatran and rivaroxaban, is surging due to their ease of use, minimal drug interactions, and lower bleeding risks, which is propelling market expansion. However, challenges like heightened bleeding risks, the high expense of NOACs, gastrointestinal complications, stringent regulations, and apprehension about side effects continue to constrain market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antithrombotic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antithrombotic Drugs Market Segments Analysis

Global Antithrombotic Drugs Market is segmented by Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel and region. Based on Type, the market is segmented into Apixaban, Debigatran, Edoxaban, Fondaparinux, Heparin and Rivaroxaban. Based on Drug Class, the market is segmented into Thrombolytic Drugs, Anti-Platelet Drugs, Anticoagulants and Others. Based on Indication, the market is segmented into Atrial Fibrillation, Stroke, Deep vein thrombosis (DVT), Pulmonary Embolism (PE) and Others. Based on Route of Administration, the market is segmented into Oral, Injectable and Others. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antithrombotic Drugs Market

The increasing incidence of cardiovascular conditions such as atrial fibrillation, deep vein thrombosis, and stroke significantly drives the demand for antithrombotic drugs. Contributing factors include an expanding population, sedentary lifestyles, and the prevalence of metabolic syndrome, which together highlight the critical role of anticoagulants and antiplatelet medications. These therapies are essential not only for the immediate management of acute events but also for the long-term reduction of cardiovascular risks. As awareness of these health issues continues to rise, the market for antithrombotic medications is expected to expand, reflecting the need for effective treatment options.

Restraints in the Global Antithrombotic Drugs Market

The Global Antithrombotic Drugs market faces significant challenges due to the inherent risk of bleeding associated with these medications, particularly for elderly patients or individuals with pre-existing health conditions. This elevated risk complicates clinical decision-making processes, often necessitating continuous monitoring, adjustments in dosage, or even discontinuation of therapy. Such safety concerns can undermine the confidence of healthcare providers and lead to decreased patient adherence to prescribed regimens. Consequently, these factors can severely impact both the overall market penetration of antithrombotic treatments and the effectiveness of long-term maintenance therapies, ultimately affecting patient outcomes.

Market Trends of the Global Antithrombotic Drugs Market

The global antithrombotic drugs market is witnessing a notable trend toward next-generation targeted therapies that promise enhanced specificity in coagulation factor modulation. This innovative approach is focused on developing ultra-targeted treatments with reduced bleeding risks and sustained therapeutic efficacy. By honing in on specific pathological processes, these advanced antithrombotic agents are designed to minimize side effects associated with traditional therapies, paving the way for more personalized treatment strategies. As a result, healthcare providers can better balance the prevention of clotting with the control of bleeding, meeting the evolving needs of patients and driving growth in the antithrombotic market.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2025
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Case Studies
  • Customer Buying Behavior Analysis

Global Antithrombotic Drugs Market Size by Type & CAGR (2026-2033)

  • Market Overview
  • Apixaban
  • Debigatran
  • Edoxaban
  • Fondaparinux
  • Heparin
  • Rivaroxaban

Global Antithrombotic Drugs Market Size by Drug Class & CAGR (2026-2033)

  • Market Overview
  • Thrombolytic Drugs
  • Anti-Platelet Drugs
  • Anticoagulants
  • Others

Global Antithrombotic Drugs Market Size by Indication & CAGR (2026-2033)

  • Market Overview
  • Atrial Fibrillation
  • Stroke
  • Deep vein thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Others

Global Antithrombotic Drugs Market Size by Route of Administration & CAGR (2026-2033)

  • Market Overview
  • Oral
  • Injectable
  • Others

Global Antithrombotic Drugs Market Size by End User & CAGR (2026-2033)

  • Market Overview
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Global Antithrombotic Drugs Market Size by Distribution Channel & CAGR (2026-2033)

  • Market Overview
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Global Antithrombotic Drugs Market Size & CAGR (2026-2033)

  • North America (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
    • US
    • Canada
  • Europe (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Type, Drug Class, Indication, Route of Administration, End User, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teva Pharmaceutical Industries Ltd. (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (U.S.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc (U.K.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (U.S.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Allergan (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca (U.K.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson Private Limited (U.S.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hikma Pharmaceuticals PLC (U.K.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Fresenius Kabi AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eisai Co., Ltd. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb Company (U.S.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • DAIICHI SANKYO COMPANY, LIMITED (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations